 Tyler Robin
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 13 | 2025 | 344 | 4.130 |
Why?
| | Small Cell Lung Carcinoma | 6 | 2023 | 96 | 2.640 |
Why?
| | Brain Neoplasms | 10 | 2023 | 1238 | 1.940 |
Why?
| | Brachytherapy | 9 | 2025 | 121 | 1.730 |
Why?
| | Prostatic Neoplasms | 9 | 2025 | 1043 | 1.650 |
Why?
| | Lung Neoplasms | 10 | 2023 | 2526 | 1.540 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2023 | 257 | 1.510 |
Why?
| | Cranial Irradiation | 4 | 2020 | 70 | 1.390 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 1081 | 1.060 |
Why?
| | Prostate-Specific Antigen | 2 | 2021 | 162 | 0.820 |
Why?
| | Radiotherapy, Adjuvant | 4 | 2019 | 220 | 0.750 |
Why?
| | Ovarian Neoplasms | 2 | 2025 | 565 | 0.700 |
Why?
| | Melanoma | 2 | 2018 | 760 | 0.680 |
Why?
| | Standard of Care | 2 | 2021 | 72 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1079 | 0.600 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2016 | 63 | 0.580 |
Why?
| | Databases, Factual | 9 | 2024 | 1357 | 0.570 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 142 | 0.570 |
Why?
| | Prostatectomy | 1 | 2018 | 104 | 0.560 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 99 | 0.560 |
Why?
| | Radiation Oncology | 1 | 2018 | 82 | 0.550 |
Why?
| | Oncologists | 1 | 2018 | 38 | 0.550 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.540 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.540 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.540 |
Why?
| | Nose Neoplasms | 1 | 2017 | 25 | 0.540 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 28 | 0.530 |
Why?
| | Aged | 24 | 2025 | 23961 | 0.530 |
Why?
| | Chemoradiotherapy | 3 | 2019 | 225 | 0.530 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 42 | 0.500 |
Why?
| | Antibodies | 1 | 2018 | 410 | 0.500 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 249 | 0.500 |
Why?
| | Physician's Role | 1 | 2018 | 211 | 0.500 |
Why?
| | Submandibular Gland | 1 | 2015 | 20 | 0.470 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 322 | 0.460 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2014 | 172 | 0.450 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 683 | 0.450 |
Why?
| | Radiotherapy Dosage | 6 | 2025 | 268 | 0.440 |
Why?
| | Adenocarcinoma | 2 | 2021 | 940 | 0.440 |
Why?
| | Aged, 80 and over | 11 | 2025 | 7635 | 0.420 |
Why?
| | Internet | 1 | 2018 | 655 | 0.420 |
Why?
| | Humans | 51 | 2025 | 137585 | 0.410 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 548 | 0.410 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2012 | 25 | 0.390 |
Why?
| | RNA-Binding Protein EWS | 1 | 2012 | 26 | 0.390 |
Why?
| | Liver Neoplasms | 1 | 2018 | 786 | 0.380 |
Why?
| | Middle Aged | 23 | 2025 | 33479 | 0.370 |
Why?
| | Genital Neoplasms, Female | 2 | 2023 | 90 | 0.370 |
Why?
| | Head and Neck Neoplasms | 1 | 2017 | 606 | 0.360 |
Why?
| | Neoadjuvant Therapy | 4 | 2018 | 404 | 0.360 |
Why?
| | Combined Modality Therapy | 6 | 2025 | 1236 | 0.360 |
Why?
| | Sarcoma, Ewing | 1 | 2012 | 97 | 0.350 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1389 | 0.350 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 938 | 0.340 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 215 | 0.330 |
Why?
| | Female | 28 | 2025 | 73304 | 0.330 |
Why?
| | Healthcare Disparities | 1 | 2016 | 654 | 0.320 |
Why?
| | Bone Neoplasms | 1 | 2012 | 247 | 0.320 |
Why?
| | Androgen Antagonists | 3 | 2024 | 82 | 0.310 |
Why?
| | Male | 21 | 2025 | 67762 | 0.280 |
Why?
| | Endometrial Neoplasms | 2 | 2021 | 201 | 0.280 |
Why?
| | Margins of Excision | 2 | 2019 | 50 | 0.280 |
Why?
| | Hysterectomy | 2 | 2019 | 129 | 0.280 |
Why?
| | Retrospective Studies | 12 | 2024 | 15657 | 0.270 |
Why?
| | Neoplasms | 2 | 2020 | 2671 | 0.270 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2017 | 43 | 0.270 |
Why?
| | Lymph Nodes | 2 | 2021 | 491 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2022 | 10811 | 0.240 |
Why?
| | Survival Analysis | 3 | 2018 | 1325 | 0.240 |
Why?
| | MicroRNAs | 1 | 2012 | 692 | 0.240 |
Why?
| | Neoplasm Metastasis | 3 | 2017 | 658 | 0.230 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1396 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1692 | 0.230 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1502 | 0.230 |
Why?
| | Hematuria | 1 | 2024 | 12 | 0.220 |
Why?
| | Adult | 14 | 2025 | 37929 | 0.220 |
Why?
| | Carcinoma, Small Cell | 1 | 2024 | 172 | 0.220 |
Why?
| | Fiducial Markers | 1 | 2023 | 9 | 0.210 |
Why?
| | Prognosis | 4 | 2024 | 4030 | 0.200 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 51 | 0.200 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5131 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 118 | 0.200 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2022 | 130 | 0.190 |
Why?
| | Lymphatic Metastasis | 1 | 2021 | 352 | 0.170 |
Why?
| | Young Adult | 8 | 2024 | 13209 | 0.160 |
Why?
| | Breast Neoplasms | 4 | 2019 | 2253 | 0.160 |
Why?
| | Simulation Training | 1 | 2021 | 106 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2018 | 389 | 0.160 |
Why?
| | Carcinosarcoma | 1 | 2018 | 21 | 0.150 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1266 | 0.150 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 35 | 0.150 |
Why?
| | Survival Rate | 3 | 2019 | 1972 | 0.150 |
Why?
| | Aquaporin 4 | 1 | 2019 | 94 | 0.150 |
Why?
| | Radiometry | 1 | 2018 | 50 | 0.140 |
Why?
| | Enterococcus faecalis | 1 | 1998 | 26 | 0.140 |
Why?
| | Urine | 1 | 1998 | 59 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 246 | 0.140 |
Why?
| | India | 1 | 2018 | 195 | 0.140 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2018 | 34 | 0.140 |
Why?
| | Biopsy | 1 | 2021 | 1129 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1313 | 0.140 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 1998 | 70 | 0.140 |
Why?
| | Salvage Therapy | 1 | 2018 | 142 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 109 | 0.140 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 431 | 0.140 |
Why?
| | Thymus Neoplasms | 1 | 2017 | 25 | 0.130 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 40 | 0.130 |
Why?
| | Thymoma | 1 | 2017 | 36 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 190 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 70 | 0.130 |
Why?
| | Machine Learning | 1 | 2021 | 493 | 0.130 |
Why?
| | Database Management Systems | 1 | 2016 | 51 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 1998 | 188 | 0.120 |
Why?
| | Alphapapillomavirus | 1 | 2016 | 39 | 0.120 |
Why?
| | Patient Preference | 1 | 2018 | 191 | 0.120 |
Why?
| | Organs at Risk | 1 | 2015 | 32 | 0.120 |
Why?
| | Propensity Score | 1 | 2017 | 294 | 0.120 |
Why?
| | Forecasting | 1 | 2017 | 389 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 34 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 261 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1477 | 0.110 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 57 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 786 | 0.110 |
Why?
| | Patient Selection | 1 | 2018 | 696 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.110 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 343 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2015 | 145 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 1 | 2024 | 2691 | 0.110 |
Why?
| | Disease Progression | 2 | 2018 | 2757 | 0.100 |
Why?
| | United States | 8 | 2024 | 14841 | 0.100 |
Why?
| | Quality of Life | 1 | 2025 | 2892 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1509 | 0.100 |
Why?
| | Mass Screening | 1 | 2021 | 1287 | 0.100 |
Why?
| | Genes, Tumor Suppressor | 1 | 2012 | 86 | 0.090 |
Why?
| | Etoposide | 1 | 2012 | 158 | 0.090 |
Why?
| | Adolescent | 7 | 2024 | 21513 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2111 | 0.090 |
Why?
| | Internship and Residency | 1 | 2021 | 1147 | 0.090 |
Why?
| | Feasibility Studies | 1 | 2015 | 956 | 0.090 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2014 | 455 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 806 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 3412 | 0.090 |
Why?
| | Doxorubicin | 1 | 2012 | 362 | 0.080 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 209 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2023 | 614 | 0.080 |
Why?
| | Cell Movement | 1 | 2014 | 967 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 480 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 411 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2014 | 712 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1120 | 0.080 |
Why?
| | Prospective Studies | 2 | 2023 | 7604 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2129 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 801 | 0.070 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2006 | 150 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2017 | 6079 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5778 | 0.060 |
Why?
| | Thiohydantoins | 1 | 2024 | 6 | 0.060 |
Why?
| | Androstenes | 1 | 2024 | 18 | 0.060 |
Why?
| | Phenylthiohydantoin | 1 | 2024 | 42 | 0.060 |
Why?
| | Androgen Receptor Antagonists | 1 | 2024 | 34 | 0.060 |
Why?
| | Cystoscopy | 1 | 2024 | 21 | 0.050 |
Why?
| | Infant | 2 | 2017 | 9465 | 0.050 |
Why?
| | Risk Assessment | 2 | 2024 | 3457 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 172 | 0.050 |
Why?
| | Benzamides | 1 | 2024 | 216 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2012 | 2475 | 0.050 |
Why?
| | Child, Preschool | 2 | 2017 | 11074 | 0.050 |
Why?
| | Hormones | 1 | 2023 | 143 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | Child | 3 | 2021 | 21935 | 0.050 |
Why?
| | Developing Countries | 1 | 2023 | 307 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 740 | 0.040 |
Why?
| | Pyrazoles | 1 | 2024 | 423 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 234 | 0.040 |
Why?
| | Health Care Costs | 1 | 2024 | 398 | 0.040 |
Why?
| | Species Specificity | 2 | 1998 | 585 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 759 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3566 | 0.040 |
Why?
| | Yersinia Infections | 1 | 1979 | 4 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 38 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 1998 | 120 | 0.040 |
Why?
| | Bacteriological Techniques | 1 | 1998 | 73 | 0.040 |
Why?
| | Culture Media | 1 | 1998 | 165 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2018 | 150 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 257 | 0.030 |
Why?
| | SEER Program | 1 | 2018 | 227 | 0.030 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 341 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 698 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2031 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3284 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 992 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1943 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2014 | 86 | 0.030 |
Why?
| | Calorimetry | 1 | 2014 | 70 | 0.030 |
Why?
| | Allosteric Regulation | 1 | 2014 | 97 | 0.030 |
Why?
| | Clinical Competence | 1 | 2021 | 1118 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2014 | 114 | 0.030 |
Why?
| | Magnesium | 1 | 2014 | 156 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2014 | 385 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 2074 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6828 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 476 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 340 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 180 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5742 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1774 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2668 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 840 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2035 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2139 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2900 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2847 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 2224 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4295 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2011 | 399 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1050 | 0.020 |
Why?
| | Cyclin B1 | 1 | 2006 | 6 | 0.020 |
Why?
| | Cyclin B | 1 | 2006 | 15 | 0.020 |
Why?
| | Cyclin A | 1 | 2006 | 17 | 0.020 |
Why?
| | Maleimides | 1 | 2006 | 23 | 0.020 |
Why?
| | Cyclin E | 1 | 2006 | 25 | 0.020 |
Why?
| | G2 Phase | 1 | 2006 | 38 | 0.020 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2006 | 73 | 0.020 |
Why?
| | Flavonoids | 1 | 2006 | 85 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 121 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2012 | 1096 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 152 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 185 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2006 | 261 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10388 | 0.010 |
Why?
| | Cell Division | 1 | 2006 | 794 | 0.010 |
Why?
| | Indoles | 1 | 2006 | 412 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2553 | 0.010 |
Why?
| | Animals | 2 | 2018 | 36940 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1759 | 0.010 |
Why?
| | Mice | 1 | 2018 | 17787 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 916 | 0.010 |
Why?
| | Yersinia | 1 | 1979 | 2 | 0.010 |
Why?
| | Serotyping | 1 | 1979 | 32 | 0.010 |
Why?
| | New York City | 1 | 1979 | 85 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5079 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2833 | 0.010 |
Why?
|
|
Robin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|